Determining Individualized Cancer Therapy in Pancreatic Cancer
- Conditions
- Pancreatic Neoplasms
- Registration Number
- NCT05914987
- Lead Sponsor
- Medical College of Wisconsin
- Brief Summary
This is a non-therapeutic exploratory observational precision oncology study designed to collect and analyze data that demonstrate the clinical efficacy and tolerability of personalized treatments based on molecular tumor profiling assessments (i.e., matched therapy) in adult pancreatic cancer patients. Patient medical records, obtained both retrospectively and prospectively, will be examined for results of molecular profiling obtained through standard of care testing to help understand how well molecular testing might predicts response to therapy. Patient demographic and outcome parameters to be evaluated include, but are not limited to, tumor response, time to treatment failure, patient survival, and toxicity.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 1000
- Age ≥18 years.
- Pathologically confirmed pancreatic cancer.
- Ability to understand a written informed consent document and the willingness to sign it
- Age <18 years.
- Primary cancer diagnosis other than pancreatic cancer.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Number of Subjects Receiving Targeted Therapy 5 years This measure is the number of study subject's whose treating physician prescribes and subsequently receives the therapeutic recommendation of the Molecular Tumor Board.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Froedtert Hospital and the Medical College of Wisconsin
🇺🇸Milwaukee, Wisconsin, United States